In June 2025, the NPPA conducted a review of non-scheduled formulations, including acetylsalicylic acid, to assess market prices and ensure affordability. Although no immediate price controls were implemented, the review highlighted the government's commitment to monitoring essential medicine prices.
In September 2025, the WHO updated its Good Manufacturing Practices guidelines, emphasizing stricter quality control measures for pharmaceutical exports. Indian manufacturers exporting "Disprin" must align with these enhanced standards to maintain market access, particularly in countries adhering to WHO recommendations.
In December 2025, the EMA issued a directive requiring additional safety labeling for acetylsalicylic acid products, focusing on gastrointestinal risks associated with long-term use. Exporters targeting the European market must update their product information to comply with this directive.
In February 2026, the CDSCO introduced an expedited approval process for generic drugs, including acetylsalicylic acid formulations, to encourage domestic production and export. This policy aims to streamline regulatory procedures and bolster India's position as a leading pharmaceutical exporter.
In March 2026, the World Trade Organization (WTO) reported a 5% increase in global demand for analgesic medications, including acetylsalicylic acid, driven by rising healthcare needs in developing countries. This trend presents growth opportunities for Indian exporters of "Disprin."
